Jonathan Gardner
Senior Reporter | @ByJonGardner1058 articles by Jonathan Gardner
-
CMS sets 2027 Medicare prices for Wegovy, Trelegy and 13 other drugs
Nov. 26, 2025 -
Novartis wins approval to use SMA gene therapy in older patients
Nov. 25, 2025 -
Bayer’s experimental blood-thinner notches trial win in stroke prevention
Nov. 24, 2025 -
Eli Lilly becomes first drugmaker to hit $1 trillion in market value
Nov. 21, 2025 -
GSK, Anaptysbio sue each other over Jemperli revenue
Nov. 21, 2025 -
Agios shares fall on mixed sickle cell results for blood disease drug
Nov. 19, 2025 -
Roche pill notches win in early breast cancer
Nov. 18, 2025 -
J&J adds to pharma’s M&A spree with $3B buyout of startup Halda
Nov. 17, 2025 -
Bristol Myers, J&J’s new blood thinner fails first big test
Nov. 14, 2025 -
Day One snaps up ADC maker Mersana in backloaded buyout deal
Nov. 13, 2025 -
Merck showcases data suggesting PCSK9 pill might rival cholesterol-lowering shots
Nov. 10, 2025 -
Novo, Lilly cut deal with Trump to lower prices of obesity drugs
Nov. 6, 2025 -
FTC signals scrutiny of Novo’s bid for Metsera
Nov. 5, 2025 -
Metsera again chooses Novo as bidding war with Pfizer intensifies
Nov. 4, 2025 -
Caribou results suggest renewed promise for ‘off-the-shelf’ cancer cell therapy
Nov. 3, 2025 -
Novo tops Pfizer with $6.5B bid for Metsera
Oct. 30, 2025 -
FDA, aiming to lower drug costs, moves to speed approval of biosimilars
Oct. 29, 2025 -
Lilly aligns with Walmart in bid to broaden access to discounted Zepbound
Oct. 29, 2025 -
Merck kidney cancer drug succeeds in two large trials
Oct. 28, 2025 -
Intellia pauses two CRISPR drug studies after safety scare
Oct. 27, 2025 -
Novo’s main shareholder pushes out more than half of company’s board
Oct. 21, 2025 -
Summit’s dual-acting drug scores lung cancer win
Oct. 20, 2025 -
Roche pill delays tumor progression in closely watched breast cancer study
Oct. 18, 2025 -
J&J claims success in study testing earlier Tecvayli use in multiple myeloma
Oct. 16, 2025 -
Kailera nets $600M more to advance Zepbound-like obesity drug
Oct. 14, 2025